ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.
Ezra Y Rosen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.